CD274 and Merkel cell skin cancer: Avelumab, an anti-programmed death-ligand 1 (PD-L1) inhibitor, was the first FDA-approved drug for MCC in March 2017, and pembrolizumab, an anti-PD-1 inhibitor, was approved in December 2018.